The Claim
Topical application of 0.9% pregabalin eye drops reduces intraocular pressure by up to 30% in mice carrying the Cacna2d1 B haplotype, while producing minimal effect in mice carrying the Cacna2d1 D haplotype.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice with a specific genetic variant (Cacna2d1 B haplotype), eye drops containing 0.9% pregabalin lower eye pressure by up to 30%. In mice with a different genetic variant (Cacna2d1 D haplotype), the same eye drops have little to no effect on eye pressure.
See the scientific wording
Pregabalin, when applied topically as eye drops at 0.9% concentration, reduces intraocular pressure by up to 30% in mice carrying the Cacna2d1 B haplotype, but has minimal effect in mice with the D haplotype, indicating a genotype-dependent therapeutic response.
Pregabalin attaches to a specific protein in the eye that controls calcium flow. When calcium enters less, the eye produces less fluid and drains it better, which lowers pressure inside the eye. This only happens if the person has a certain version of the gene that makes this protein work properly.
What the research says
1 studyPregabalin eye drops lower eye pressure in some mice but not others — it only works if they have a specific version of a gene. The study proved this exact thing.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.